title: Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
abstract: The therapeutic efficacy of the immunoglobulin G1 (IgG1) monoclonal antibody (MAb) 2H1 to the Cryptococcus neoformans capsular polysaccharide was studied with and without amphotericin B (AmB) in a murine model of intravenous (i.v.) infection. MAb and AmB were administered by intraperitoneal (i.p.) injection after i.v. infection with a C. neoformans serotype D strain. Intraperitoneal administration of MAb 2H1 resulted in rapid distribution to the intravascular compartment, and the half-lives of i.p. and i.v. administered MAb were similar. Administration of MAb 2H1 alone resulted in increased survival, decreased lung fungal burden, and reduced serum glucuronoxylomannan antigen levels when given 2 to 6 h but not 24 h after infection. In vivo, the combination of MAb 2H1 and AmB was more effective at prolonging survival than either agent alone. MAbs of IgM, IgG1, IgG3, and IgA isotypes given 1 day after infection were effective in reducing serum GXM-D levels, with their relative efficacy being IgG1 > IgG3 > IgM > IgA. In vitro, MAb 2H1 was a potent opsonin of C. neoformans and the combination of MAb 2H1 and AmB was more effective than either agent alone in decreasing C. neoformans colony counts in the presence of the murine macrophage cell line J774.16. The results confirm that capsule-binding MAbs can enhance the effect of AmB against C. neoformans and provide support for considering combined therapy in humans.
authors.affiliation: Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461.
authors.forename: J
authors.initials: J
authors.lastname: Mukherjee
authors.forename: L S
authors.initials: LS
authors.lastname: Zuckier
authors.forename: M D
authors.initials: MD
authors.lastname: Scharff
authors.forename: A
authors.initials: A
authors.lastname: Casadevall
mesh_terms: D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D002460:Cell Line; D003131:Combined Modality Therapy; D003453:Cryptococcosis / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D003455:Cryptococcus neoformans / Q000276:immunology*; D005260:Female; D007274:Injections, Intraperitoneal; D008168:Lung / Q000382:microbiology; D008264:Macrophages / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008805:Mice, Inbred A; D010587:Phagocytosis / Q000187:drug effects; D011134:Polysaccharides / Q000097:blood / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D011134:Polysaccharides; C027478:glucuronoxylomannan; D000666:Amphotericin B